Mammalian transient protein expression market players eye opportunities in biopharma

Global mammalian transient protein market revenues are projected to surpass US$ 540 million in 2020, according to a new study by Future Market Insights. The report also states that, innovations in automation and recombinant proteins will support market developments, however, prohibitive costs and complexity to maintain media purity remain challenges.

Key takeaways on mammalian transient protein expression market:

  • The size of the mammalian transient protein expression market is estimated to reach approximately US$540 million by the end of 2020, with antibody and therapeutic protein production applications being the primary factors driving growth in the industry.
  • Biopharmaceutical companies will remain prominent end-users of mammalian transient protein expression, while CROs are also likely to reflect steady growth on the back of biologics and drug development endeavours.
  • Chinese hamster ovary cells in terms of cell lines reflect relatively higher demand, owing to applications in academic and research uses, accounting for ~70% of market share by 2030.
  • North America followed by Europe are leading markets for mammalian transient protein expression, access to cutting edge healthcare technologies, and the presence of leading market players.

“A significant increase in R&D activities biopharmaceutical, pharmaceutical, and biotechnology market participants to develop and manufacture advanced biologics including monoclonal antibodies, vaccines, and therapeutic proteins is driving demand for mammalian transient protein expression. Also, investments into drug development is important to propel long-term growth,” said a lead analyst.

COVID-19 impact

The impact of the COVID-19 pandemic on the mammalian transient protein expression market has largely been negative. Strict lockdown and social distancing regulations has resulted in delayed projects in research and biomedicine applications.

Also, market players have witnessed lower sales and revenue during the crisis period arising from supply chain disruptions, and shortage of adequate manpower. On the other hand, potential for applications in vaccine development is likely to provide opportunities for short-term growth, moderately mitigating loss during this period.

Who is winning?

In its latest report, study provides details on key business strategies that are gaining importance in the mammalian transient protein expression market. Market leaders in the industry have been pushing on the expansion of their portfolios with offerings associated to antibody development and gene coding. Also, strategic collaborations are gaining ground in the sector.

Merck KgaA, Thermo Fisher Scientific, Agilent Technologies, Lonza, Mirus Bio., Takara Bio., Qiagenand Bio-Rad Laboratories  are some of the key companies operating in the mammalian transient protein expression market.

Image credit: National Cancer Institute


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free